Market research
ALTER.PA Theradiag SA
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 17M
- P/E ratio
- 42.0
- Analyst target
- 3.8
- Dividend yield
- Not available
- Beta
- -0.27
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- FR0004197747
- Market cap
- 17M
- P/E ratio
- 42.0
- Analyst target
- 3.8
- Dividend yield
- Not available
- Beta
- -0.27
About
About Theradiag SA
Theradiag SA develops, manufactures, and markets in-vitro diagnostic products in France and internationally. The company offers LISA tracker, a tool for the monitoring of biotherapies; i-Tracker, a random access solution for therapeutic drug monitoring of biologics; i-Track10 for measurement of drug level and anti-drug antibodies; ez-Track 1 and ez-Tracker, a true point-of-care solution for therapeutic drug monitoring of biologics; and Immunotrol Tracker, a ready-to-use internal quality control sera for pharmacological dosage of biotherapies. It also provides autoimmune reagents for connective tissue diseases, rheumatoid arthritis, autoimmune liver diseases, vasculitis, celiac disease, anti-phospholipids syndrome, autoimmune thryroiditis, pernicious anemia, and other autoimmune diseases; IMMUNO-TROL, a multi-parametric precision control in autoimmunity; SQA-V system, a semen analyzer; V-Sperm for loading results, pictures, and videos of the samples into the computer; and rapid tests for colorectal cancer. In addition, the company offers instrumentation, including FIDIS system for simultaneous and specific detection of multiple analytes from the same sample in a single assay; and Theralis that integrates multiplex FIDIS immunofluorescence and ELISA. Theradiag SA was incorporated in 1986 and is based in Marne-la-Vallée, France. Theradiag SA operates as a subsidiary of Biosynex SA.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALTER.PA discussion.
5 years, 5 months ago
Theradiag SA is currently in a long term downtrend where the price is trading 26.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
Finally, its free cash flow fell by 0.0% to $-426K since the same quarter in the previous year.
Based on the above factors, Theradiag SA gets an overall score of 1/5.